[go: up one dir, main page]

SMT201600235B - Predittori per il trattamento del cancro - Google Patents

Predittori per il trattamento del cancro

Info

Publication number
SMT201600235B
SMT201600235B SM201600235T SM201600235T SMT201600235B SM T201600235 B SMT201600235 B SM T201600235B SM 201600235 T SM201600235 T SM 201600235T SM 201600235 T SM201600235 T SM 201600235T SM T201600235 B SMT201600235 B SM T201600235B
Authority
SM
San Marino
Prior art keywords
predictors
cancer treatment
cancer
treatment
Prior art date
Application number
SM201600235T
Other languages
English (en)
Inventor
Deborah Ricci
Weimin Li
Erin Devay Henitz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SMT201600235B publication Critical patent/SMT201600235B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/575
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • G01N33/57557
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
SM201600235T 2011-08-11 2016-07-15 Predittori per il trattamento del cancro SMT201600235B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522596P 2011-08-11 2011-08-11
US201161560555P 2011-11-16 2011-11-16
PCT/US2012/049941 WO2013022935A1 (en) 2011-08-11 2012-08-08 Predictors for cancer treatment

Publications (1)

Publication Number Publication Date
SMT201600235B true SMT201600235B (it) 2016-08-31

Family

ID=47668910

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600235T SMT201600235B (it) 2011-08-11 2016-07-15 Predittori per il trattamento del cancro

Country Status (19)

Country Link
US (1) US9322066B2 (it)
EP (1) EP2742356B1 (it)
JP (1) JP6002222B2 (it)
CN (1) CN103930785B (it)
AU (1) AU2012294493B2 (it)
CA (1) CA2844825A1 (it)
CY (1) CY1117838T1 (it)
DK (1) DK2742356T3 (it)
ES (1) ES2586328T3 (it)
HR (1) HRP20160851T1 (it)
HU (1) HUE029295T2 (it)
MX (1) MX357429B (it)
PL (1) PL2742356T3 (it)
PT (1) PT2742356E (it)
RS (1) RS55053B1 (it)
RU (1) RU2600026C2 (it)
SI (1) SI2742356T1 (it)
SM (1) SMT201600235B (it)
WO (1) WO2013022935A1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130342542A1 (en) * 2012-06-22 2013-12-26 Quintiles Transnational Corp. Method and System To Manipulate Multiple Selections Against a Population of Elements
US10795879B2 (en) 2012-06-22 2020-10-06 Iqvia Inc. Methods and systems for predictive clinical planning and design
US20170128518A1 (en) * 2014-07-01 2017-05-11 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
KR102422975B1 (ko) 2014-09-10 2022-07-20 리텐스 오토모티브 파트너쉽 비틀림 스프링력을 이용하는 비례 감쇠형 동력 전달 장치
WO2017218970A1 (en) * 2016-06-17 2017-12-21 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
WO2018176147A1 (en) 2017-03-28 2018-10-04 Litens Automotive Partnership Isolation device with selected angle between spring stop and damping member
EP3705584A1 (en) 2019-03-05 2020-09-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method of identifying patients with bortezomib resistant multiple myeloma and other blood diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
CA2435124A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
ES2542328T3 (es) * 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
CN100366636C (zh) * 2004-12-08 2008-02-06 中国农业科学院畜牧研究所 猪生产及免疫性状相关蛋白,它的编码基因与应用
KR100653990B1 (ko) 2004-12-29 2006-12-05 주식회사 하이닉스반도체 포토마스크 데이터베이스 패턴의 불량 검사 방법
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
CA2660275A1 (en) 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2009148528A2 (en) 2008-05-30 2009-12-10 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment

Also Published As

Publication number Publication date
CN103930785A (zh) 2014-07-16
JP2014524571A (ja) 2014-09-22
DK2742356T3 (en) 2016-05-23
CY1117838T1 (el) 2017-05-17
HUE029295T2 (en) 2017-02-28
MX357429B (es) 2018-07-09
MX2014001619A (es) 2014-11-10
US20130216524A1 (en) 2013-08-22
PL2742356T3 (pl) 2016-11-30
AU2012294493B2 (en) 2017-02-23
EP2742356B1 (en) 2016-04-27
SI2742356T1 (sl) 2016-06-30
JP6002222B2 (ja) 2016-10-05
PT2742356E (pt) 2016-06-06
HK1199097A1 (zh) 2015-06-19
HK1199094A1 (en) 2015-06-19
RS55053B1 (sr) 2016-12-30
US9322066B2 (en) 2016-04-26
RU2014108986A (ru) 2015-09-20
WO2013022935A1 (en) 2013-02-14
CN103930785B (zh) 2016-05-18
EP2742356A1 (en) 2014-06-18
RU2600026C2 (ru) 2016-10-20
AU2012294493A1 (en) 2014-02-20
ES2586328T3 (es) 2016-10-13
HRP20160851T1 (hr) 2016-09-23
CA2844825A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
IL267242B (en) Cancer treatment
LT2707030T (lt) Vėžio gydymas
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
BR112014007603A2 (pt) métodos de tratamento do câncer
HUE046667T2 (hu) Rák kombinatív kezelése
LT3026064T (lt) Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
PT2897620T (pt) Método de tratamento de cancro
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
BR112014002200A2 (pt) tratamento de câncer de mama
IL237558A0 (en) Methods for the treatment of locally advanced breast cancer
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
BR112014012880A2 (pt) tratamento imunogênico do câncer
SMT201600235B (it) Predittori per il trattamento del cancro
EP2685823A4 (en) CANCER TREATMENT
DK2892535T3 (da) Fremgangsmåde til adjuverende cancerbehandling
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
DK2872176T3 (en) Cancer treatment
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ME03035B (me) Kombinacijska terapija raka jajnika
GB201106630D0 (en) Cancer therapy
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201222563D0 (en) Cancer treatment
BR112015008366A2 (pt) método de tratamento de câncer
GB201116328D0 (en) Treatment for tumours